Gapping down
In reaction to disappointing earnings/guidance: XXIA -5%, FMC -1.8%.
Select EU financial related names showing weakness:NBG -3%, IRE -2.4%, RBS -1.4%, ING -1.1%, DB -0.8%.
Other news: MTOR -15.4% (reaches agreement with Eaton (ETN) to Settle Antitrust Lawsuit), BIOA -5% (secures CAD20 mln loan for Sarnia plant, light volume), KNDI -4.7% (files for $300 mln mixed securities shelf offering).
Analyst comments: ENBL -2.4% (initiated with a Market Perform at Wells Fargo), NGHC -2% (downgraded to Neutral from Buy at Guggenheim), NVDA -2% (downgraded to Underperform from Sector Perform at Pacific Crest), PER -1.5% (downgraded to Mkt Perform from Outperform at Raymond James), TDC -1.3% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities), SPWR-1.2% (downgraded to Hold from Buy at Brean Capital), COH -1.2% (downgraded to Underperform from Neutral at Wedbush)
In reaction to disappointing earnings/guidance: XXIA -5%, FMC -1.8%.
Select EU financial related names showing weakness:NBG -3%, IRE -2.4%, RBS -1.4%, ING -1.1%, DB -0.8%.
Other news: MTOR -15.4% (reaches agreement with Eaton (ETN) to Settle Antitrust Lawsuit), BIOA -5% (secures CAD20 mln loan for Sarnia plant, light volume), KNDI -4.7% (files for $300 mln mixed securities shelf offering).
Analyst comments: ENBL -2.4% (initiated with a Market Perform at Wells Fargo), NGHC -2% (downgraded to Neutral from Buy at Guggenheim), NVDA -2% (downgraded to Underperform from Sector Perform at Pacific Crest), PER -1.5% (downgraded to Mkt Perform from Outperform at Raymond James), TDC -1.3% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities), SPWR-1.2% (downgraded to Hold from Buy at Brean Capital), COH -1.2% (downgraded to Underperform from Neutral at Wedbush)